Search results
Showing 1 to 15 of 378 results for heart failure
This guideline covers diagnosing and managing acute heart failure or possible acute heart failure in people aged 18 and over. It aims to improve the immediate care of someone who is acutely unwell as a result of heart failure.
Chronic heart failure in adults: diagnosis and management (NG106)
This guideline covers diagnosing and managing chronic heart failure in people aged 18 and over. It aims to improve diagnosis and treatment to increase the length and quality of life for people with heart failure.
This quality standard covers the care of adults (aged 18 and over) with suspected or confirmed acute heart failure. It describes high-quality care in priority areas for improvement.
View quality statements for QS103Show all sections
Sections for QS103
- Quality statements
- Quality statement 1: Single measurement of natriuretic peptide
- Quality statement 2: Transthoracic doppler 2D echocardiography
- Quality statement 3: Organisation of care – early specialist input
- Quality statement 4: Starting or continuing beta-blocker treatment
- Quality statement 5: Drug therapy
- Quality statement 6: Follow-up clinical assessment
- About this quality standard
All NICE products on heart failure. Includes any guidance, advice and quality standards.
This quality standard covers assessing, diagnosing and managing chronic heart failure in adults (aged 18 and over). It describes high-quality care in priority areas for improvement. Statements cover adults with chronic heart failure with reduced ejection fraction and adults with chronic heart failure with preserved ejection fraction, unless otherwise stated.
View quality statements for QS9Show all sections
Sections for QS9
- Quality statements
- Quality statement 1: N-terminal pro-B-type natriuretic peptide measurement
- Quality statement 2: Specialist assessment
- Quality statement 3: Medication for chronic heart failure with reduced ejection fraction
- Quality statement 4: Review after changes in medication
- Quality statement 5: Review of people with chronic heart failure
- Quality statement 6: Cardiac rehabilitation
- Update information
Evidence-based recommendations on ivabradine (Procoralan) for treating chronic heart failure in adults.
Awaiting development [GID-MT609] Expected publication date: TBC
In development [GID-NG10405] Expected publication date: TBC
Empagliflozin for treating chronic heart failure with reduced ejection fraction (TA773)
Evidence-based recommendations on empagliflozin (Jardiance) for treating chronic heart failure with reduced ejection fraction in adults.
Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679)
Evidence-based recommendations on dapagliflozin (Forxiga) for symptomatic chronic heart failure with reduced ejection fraction in adults.
Evidence-based recommendations on dapagliflozin (Forxiga) for treating chronic heart failure with preserved or mildly reduced ejection fraction in adults.
Evidence-based recommendations on sacubitril valsartan (Entresto) for treating symptomatic chronic heart failure with reduced ejection fraction.
Evidence-based recommendations on implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy (CRT) for arrhythmias and heart failure
Awaiting development [GID-TA10393] Expected publication date: TBC
Evidence-based recommendations on empagliflozin (Jardiance) for treating chronic heart failure with preserved or mildly reduced ejection fraction in adults.